Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
ID: 347224Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/347224

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-148.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)," aimed at supporting research on the long-term cardiopulmonary effects following tuberculosis (TB) treatment. This initiative seeks applications for epidemiological and observational studies that investigate adverse outcomes and morbidity associated with post-TB lung disease, particularly in both adult and pediatric populations, with a focus on individuals affected by HIV. Understanding the implications of post-TB lung disease is crucial for improving healthcare strategies and patient management for TB survivors. Interested applicants can find more information and submission guidelines at the NIH website, with applications due by May 7, 2026. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-148-Full-Announcement.html
    PAR-23-148.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has announced a Notice of Funding Opportunity (NOFO) titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)." This initiative aims to fund research that explores the long-term cardiopulmonary effects of tuberculosis (TB) treatment, emphasizing studies on both adult and pediatric cohorts, particularly regarding adverse outcomes related to post-TB lung disease (PTLD). Research proposals should focus on understanding the epidemiology, clinical manifestations, and biological mechanisms of PTLD, with an emphasis on individuals affected by HIV. Eligible applicants include higher education institutions, nonprofits, and government agencies, among others. The funding period can extend up to five years, with no budget limitations provided they reflect the project's actual needs. Applications for this grant must adhere strictly to NIH submission guidelines and are due by scheduled deadlines, with a primary goal of reducing the burden of long-term morbidity from TB. Understanding PTLD's impact on healthcare can inform better patient management and treatment strategies, ultimately improving health outcomes for TB survivors.
    Similar Opportunities
    Tuberculosis Research Units (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the establishment of multidisciplinary Tuberculosis Research Units (TBRUs) through a grant program aimed at enhancing the understanding of Mycobacterium tuberculosis (Mtb) and its interactions with the host. This initiative seeks to foster collaborative research that characterizes the roles of bacterial and host heterogeneity in infection outcomes and disease progression, with a focus on identifying determinants relevant to Mtb establishment and dissemination. The total estimated program funding is $10 million, with approximately five awards expected, and interested applicants are encouraged to begin forming collaborations in anticipation of the Notice of Funding Opportunity (NOFO) expected to be published in September 2025. For further inquiries, potential applicants can contact Richard T. Robinson, Ph.D., at richard.robinson@nih.gov or by phone at 202-607-8565.
    Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis (R01 Clinical Trial Not Allowed)." This initiative aims to solicit research applications focused on the preclinical development of lead candidate vaccines to combat Mycobacterium tuberculosis (Mtb) infection and disease, thereby enhancing the clinical pipeline of viable vaccine candidates. The program is critical for advancing public health efforts against tuberculosis, a significant global health challenge. The estimated total funding for this program is $4,730,000, with approximately five awards expected. Interested applicants can reach out to Katrin Eichelberg, MSc, PhD, at keichelberg@nih.gov or call 240-669-2921 for further information. Key deadlines include an estimated synopsis post date of September 8, 2025, and a close date of November 7, 2025, with awards anticipated to be made by July 1, 2026.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)" aimed at supporting research into the immunometabolic changes induced by HIV that may elevate the risk of tuberculosis (TB) and hepatitis B virus (HBV) in individuals on combination antiretroviral therapy (cART). This initiative seeks to fund investigator-led studies that explore the long-term effects of HIV-related alterations in immune metabolism on disease progression and treatment responses, with a focus on identifying biomarkers and innovative therapies to mitigate these risks. The grant is open to a wide range of eligible applicants, including higher education institutions, non-profits, and for-profit organizations, with no cost-sharing requirements. Interested parties should note that the application submission deadlines range from April 2025 to January 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-315.html.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk," aimed at supporting research into the immunometabolic changes induced by HIV in individuals undergoing combination antiretroviral therapy. This initiative seeks to investigate how these alterations affect immune responses and increase the risk of subsequent infections, specifically tuberculosis (TB) and hepatitis B virus (HBV). The funding opportunity is particularly significant for advancing understanding in the field of HIV-related health risks and aims to foster innovative research approaches, including the use of machine learning and AI to identify biomarkers and therapeutic targets. Eligible applicants can receive up to $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-316.html.
    Strengthening tuberculosis (TB) prevention, diagnosis, and treatment in Southeast Asia to end TB
    Centers for Disease Control-GHC
    The Centers for Disease Control and Prevention (CDC) is offering a cooperative agreement aimed at strengthening tuberculosis (TB) prevention, diagnosis, and treatment in Southeast Asia, with a focus on reducing TB burden and mortality in high-burden countries. The initiative seeks to implement innovative approaches to enhance early TB diagnosis, advance TB prevention interventions, and improve treatment outcomes for individuals affected by TB, including those with drug-resistant strains. This funding opportunity, with an estimated total of $10 million for the first fiscal year, is open to unrestricted applicants, and interested parties can reach out to the CDC at pepfarfoas@cdc.gov for further information. Applications must be submitted electronically by 11:59 PM ET on February 17, 2026, with awards expected to be announced by September 30, 2026.
    Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01), which invites researchers to apply for access to valuable biospecimens collected from an ongoing longitudinal study focused on tobacco use behaviors and health outcomes in the U.S. This initiative primarily provides urine, plasma, serum, and genomic DNA samples to support research relevant to tobacco regulations under the Family Smoking Prevention and Tobacco Control Act. The PATH Study, launched in 2011, plays a crucial role in advancing scientific understanding of tobacco use and its implications for public health. Applications will open on March 30, 2024, and close on October 31, 2026, with evaluations based on alignment with PATH objectives and the merit of proposed research. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access." This initiative aims to provide researchers with access to biospecimens from significant studies, including the Adolescent Brain Cognitive Development (ABCD) Study and the HEALthy Brain and Child Development (HBCD) Study, to enhance understanding of the genetic and environmental factors influencing health and disease throughout life. The grant is open to a wide range of eligible applicants, including tribal governments, federal agencies, and foreign institutions, with no cost-sharing requirement. Interested parties should note that the estimated award date is January 4, 2027, and they can reach out to Heather L. Kimmel at heather.kimmel@nih.gov or by phone at 301-443-6504 for further information.
    Strengthening comprehensive HIV and TB services and health systems in high-burden areas of Namibia under the President's Emergency Plan for AIDS Relief (PEPFAR)
    Centers for Disease Control-GHC
    The Centers for Disease Control and Prevention (CDC) is offering a cooperative agreement to strengthen comprehensive HIV and TB services and health systems in high-burden areas of Namibia under the President's Emergency Plan for AIDS Relief (PEPFAR). The initiative aims to enhance facility- and community-based service delivery for HIV, TB, and associated comorbidities, while supporting the Ministry of Health and Social Services (MOHSS) in overseeing government-led programs, including case management and public health response. This funding opportunity, with an estimated total of $14 million for the first fiscal year, is open to unrestricted applicants, and interested parties should submit their applications electronically by February 17, 2026, to be considered for the anticipated awards, which are expected to be announced by September 30, 2026. For further inquiries, applicants can contact the grantor at pepfarfoas@cdc.gov.
    High-Priority Research in Tobacco Regulatory Science (Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "High-Priority Research in Tobacco Regulatory Science (Clinical Trial Optional)" aimed at supporting research that informs the FDA's tobacco regulatory authorities. This initiative seeks applications for high-priority research projects that address topics such as addiction, behavior, health effects, product composition, and toxicity, with the goal of enhancing the scientific data available for tobacco product regulation. The total estimated funding for this program is $7 million, with an award ceiling of $500,000 and an expected eight awards to be made. Interested applicants can reach out to Erik Rodriquez, Ph.D., M.P.H., at TRSP@nih.gov or by phone at 301-827-2830, with applications due by May 4, 2026, and awards expected to be announced by December 4, 2026.
    Mechanistic Exploration of Therapeutic Targets and Treatable Traits to Improve CNS Outcomes in People with HIV
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanistic Exploration of Therapeutic Targets and Treatable Traits to Improve CNS Outcomes in People with HIV." This initiative aims to support research that identifies modifiable targets and mechanisms to alleviate central nervous system (CNS) complications in individuals living with HIV, leveraging patient-derived data and innovative model platforms. The program emphasizes the importance of understanding the multifactorial nature of CNS dysfunction and seeks to accelerate the development of effective interventions through clinical studies or pre-clinical models. The estimated total funding for this program is $3 million, with approximately six awards expected. Interested applicants, particularly those with expertise in systems biology and translational neurobiology, should prepare for the upcoming Notice of Funding Opportunity (NOFO), with applications anticipated to open in September 2025. For further inquiries, potential applicants can contact Vasudev R Rao at vasudev.rao@nih.gov or by phone at 301-825-3259.